CoChat

Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors

Open access
Tiwari-Heckler, Shilpa, Gan-Schreier, Hongying, Stremmel, Wolfgang, Chamulitrat, Walee, Pathil, Anita · 2018 · Nutrients

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is associated with inefficient macro- and micronutrient metabolism, and alteration of circulating phospholipid compositions defines the signature of NAFLD. This current study aimed to assess the pattern of serum phospholipids in the spectrum of NAFLD, and its related comorbidities and genetic modifications. Methods: 97 patients with diagnosed NAFLD were recruited at a single center during 2013–2016. Based on histological and transient elastography assessment, 69 patients were divided into non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver (NAFL) subgroups. 28 patients served as healthy controls. Serum phospholipids were determined by liquid-chromatography mass spectrometry (LC-MS/MS). Results: The total content of phosphatidylcholine (PC) and sphingomyelin in the serum was significantly increased in NAFL and NASH patients, compared to healthy controls. In addition, serum lysophospatidylethanolamine levels were significantly decreased in NAFL and NASH individuals. Circulating PC species, containing linoleic and α-linolenic acids, were markedly increased in NAFLD patients with hypertension, compared to NAFLD patients without hypertension. The pattern of phospholipids did not differ between NAFLD patients with diabetes and those without diabetes. However, NAFLD patients with hyperglycemia (blood glucose level (BGL) >100 mg/dL) exhibited significantly a higher amount of monounsaturated phosphatidylethanolamine than those with low blood glucose levels. In addition, NAFLD patients with proven GG-genotype of PNPLA3, who were at higher risk for the development of progressive disease with fibrosis, showed lower levels of circulating plasmalogens, especially 16:0, compared to those with CC- and CG-allele. Conclusions: Our extended lipidomic study presents a unique metabolic profile of circulating phospholipids associated with the presence of metabolic risk factors or the genetic background of NAFLD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu10050649

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Circulating phospholipids in control (n = 28), NAFL (n = 25) and NASH (n = 42) cohorts. Results of lipid profiling of 95 patients by using LC-MS/MS method. Patients were divided in NAFL and NASH cohorts. 28 patients served as healthy control. Quantification of (A) PC; (B) PE; (C) SM; (D) LPC; (E) LPE; (F) PI; and (G) plasmalogens in the serum of healthy, NAFL and NASH patients in ng/mL serum. All the values are presented in mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = not significant (p > 0.05).
Figure 1 Circulating phospholipids in control (n = 28), NAFL (n = 25) and NASH (n = 42) cohorts. Results of lipid profiling of 95 patients by using LC-MS/MS method. Patients were divided in NAFL and NASH cohorts. 28 patients served as healthy control. Quantification of (A) PC; (B) PE; (C) SM; (D) LPC; (E) LPE; (F) PI; and (G) plasmalogens in the serum of healthy, NAFL and NASH patients in ng/mL serum. All the values are presented in mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, n.s. = not significant (p > 0.05).CC BY · PubMed Central
Figure 2 Overview of circulating phospholipids in NAFLD patients with and without hypertension. NAFLD patients were divided into patients with hypertension (with H; n = 24) and without hypertension (without H; n = 43). (A) Quantification of circulating PC and SM is represented in ng/mL serum. (B) Distribution of PC subtypes, namely saturated, mono- and poly-unsaturated PC levels, are displayed in these two groups in ng/mL serum. The total content of PC is evaluated as a sum of saturated and unsaturated PC. (C–E) Circulating PC, containing linoleic acids (PC 34:2, PC 36:2, PC 38:2) and α-linolenic acids (PC 34:3, PC 36:3, PC 38:3), are compared between hypertensive and normotensive NAFLD patients. (F,G) The amount of arachidonic acid (PC 20:4, 22:4 and 22:6) in PC is demonstrated in this graphic. All the values are presented in mean ± SEM. * p < 0.05, ** p < 0.01.
Figure 2 Overview of circulating phospholipids in NAFLD patients with and without hypertension. NAFLD patients were divided into patients with hypertension (with H; n = 24) and without hypertension (without H; n = 43). (A) Quantification of circulating PC and SM is represented in ng/mL serum. (B) Distribution of PC subtypes, namely saturated, mono- and poly-unsaturated PC levels, are displayed in these two groups in ng/mL serum. The total content of PC is evaluated as a sum of saturated and unsaturated PC. (C–E) Circulating PC, containing linoleic acids (PC 34:2, PC 36:2, PC 38:2) and α-linolenic acids (PC 34:3, PC 36:3, PC 38:3), are compared between hypertensive and normotensive NAFLD patients. (F,G) The amount of arachidonic acid (PC 20:4, 22:4 and 22:6) in PC is demonstrated in this graphic. All the values are presented in mean ± SEM. * p < 0.05, ** p < 0.01.CC BY · PubMed Central
Figure 3 MUFA-PE is increased in NAFLD patients with hyperglycemia. (A) Quantification of circulating PC, PE and SM in ng/mL serum in NAFLD patients who were divided into patients with diabetes mellitus (DM; n = 18) and without diabetes mellitus (no DM; n = 49). (B) Quantification of total PE, PUFA-PE and MUFA-PE in ng/mL serum in NAFLD patients with a BGL over 100 mg/dL (BGL > 100; n = 16) or under 100 mg/dL (BGL < 100; n = 22). All the values are presented in mean ± SEM. * p < 0.05, ** p < 0.01.
Figure 3 MUFA-PE is increased in NAFLD patients with hyperglycemia. (A) Quantification of circulating PC, PE and SM in ng/mL serum in NAFLD patients who were divided into patients with diabetes mellitus (DM; n = 18) and without diabetes mellitus (no DM; n = 49). (B) Quantification of total PE, PUFA-PE and MUFA-PE in ng/mL serum in NAFLD patients with a BGL over 100 mg/dL (BGL > 100; n = 16) or under 100 mg/dL (BGL < 100; n = 22). All the values are presented in mean ± SEM. * p < 0.05, ** p < 0.01.CC BY · PubMed Central
Figure 4 Association between plasmalogens and PNPLA3 gene polymorphism. The PNPLA3 rs738409 genotype was determined in 52 NAFLD patients. The total level of plasmalogen was the sum of plasmalogen 16:0, 18:0 and 18:1. The amount of these plasmalogen subtypes was quantified in NAFLD patients with GG- (n = 14), CC- (n = 20) and CG-allele (n = 18) of PNPLA3. Circulating plasmalogen subclasses are displayed in ng/mL serum. All the values are presented in mean ± SEM. * p < 0.05.
Figure 4 Association between plasmalogens and PNPLA3 gene polymorphism. The PNPLA3 rs738409 genotype was determined in 52 NAFLD patients. The total level of plasmalogen was the sum of plasmalogen 16:0, 18:0 and 18:1. The amount of these plasmalogen subtypes was quantified in NAFLD patients with GG- (n = 14), CC- (n = 20) and CG-allele (n = 18) of PNPLA3. Circulating plasmalogen subclasses are displayed in ng/mL serum. All the values are presented in mean ± SEM. * p < 0.05.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 96

Metadata

Authors
Tiwari-Heckler, S., Gan-Schreier, H., Stremmel, W., Chamulitrat, W., & Pathil, A.
Affiliations
  • Department of Internal Medicine IV, Gastroenterology and Hepatology, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
  • Heidelberg University (DE)
Corresponding author
Pathil, Anita
Venue
Nutrients
Publisher
MDPI AG
Published
2018-05-21
Volume
10
Issue
5
Pages
649
ISSN
2072-6643 (ISSN-L)
OpenAlex
W2803425795
Cited by
96
References
42
Citations by year
2026: 9 · 2025: 10 · 2024: 16 · 2023: 16 · 2022: 13 · 2021: 15 · 2020: 10 · 2019: 7
FWCI
6.24
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
German Research Foundation (PA 2365/1-1)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, serum phospholipids, lipidomics, phosphatidylcholine, sphingomyelin, lysophosphatidylethanolamine, plasmalogens, linoleic acid, alpha-linolenic acid, hypertension, hyperglycemia, diabetes mellitus, liver fibrosis, metabolic risk factors
MeSH terms
Acyltransferases, Adult, Chromatography, High Pressure Liquid, Female, Germany, Humans, Lipase, Male, Membrane Proteins, Middle Aged, Phospholipids, Polymorphism, Genetic, Risk Factors, Biomarkers, Comorbidity, Case-Control Studies, Spectrometry, Mass, Electrospray Ionization, Tandem Mass Spectrometry, Elasticity Imaging Techniques, Phospholipases A2, Calcium-Independent, Metabolomics, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.